| Market Cap | 68.10M | P/E | 2.69 | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -181.41M | Forward P/E | -0.66 | EPS next Y | - | 50D Avg Chg | -36.00% |
| Sales | 14.79M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -62.00% |
| Dividend | N/A | Price/Book | 0.40 | EPS next 5Y | - | 52W High Chg | -89.00% |
| Recommedations | 2.00 | Quick Ratio | 0.05 | Shares Outstanding | 21.78M | 52W Low Chg | 10.00% |
| Insider Own | 50.95% | ROA | -20.48% | Shares Float | 9.56M | Beta | 0.30 |
| Inst Own | 14.66% | ROE | -186.56% | Shares Shorted/Prior | 393.14K/388.27K | Price | 0.38 |
| Gross Margin | 21.19% | Profit Margin | - | Avg. Volume | 732,070 | Target Price | - |
| Oper. Margin | -430.51% | Earnings Date | May 20 | Volume | 703,164 | Change | -3.46% |
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Lim Kok Thay | 10% Owner 10% Owner | Jan 12 | Buy | 0.249 | 21,410,983 | 5,331,335 | 51,473,762 | 01/17/24 |
| Hariri Robert J | Chief Executive Offi.. Chief Executive Officer | Sep 29 | Buy | 0.16 | 18,422,124 | 2,947,540 | 28,570,434 | 10/10/23 |
| Diamandis Peter | Director Director | Feb 10 | Option | 0.28 | 1,071,000 | 299,880 | 1,107,145 | 02/14/23 |
| Hariri Robert J | Chief Executive Offi.. Chief Executive Officer | Nov 30 | Buy | 1.7175 | 10,000 | 17,175 | 8,074,996 | 11/30/22 |
| Hariri Robert J | Chief Executive Offi.. Chief Executive Officer | Nov 29 | Buy | 1.71 | 40,000 | 68,400 | 8,064,996 | 11/29/22 |
| Hariri Robert J | Chief Executive Offi.. Chief Executive Officer | Nov 28 | Buy | 1.74 | 40,000 | 69,600 | 8,024,996 | 11/28/22 |
| SCULLEY JOHN | Director Director | Aug 26 | Option | 0.28 | 768,594 | 215,206 | 804,739 | 08/30/22 |
| Hariri Robert J | Chief Executive Offi.. Chief Executive Officer | Aug 24 | Option | 2.87 | 119,073 | 341,740 | 7,984,996 | 08/25/22 |